Skip to Content
Merck
All Photos(1)

Key Documents

SML3517

Sigma-Aldrich

Fluindione

≥98% (HPLC)

Synonym(s):

2-(4-Fluorophenyl)-1H-indene-1,3(2H)-dione, 2-(4-Fluorophenyl)indene-1,3-dione

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C15H9FO2
CAS Number:
Molecular Weight:
240.23
MDL number:
UNSPSC Code:
51111800
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=C1C2=C(C(C1C3=CC=C(C=C3)F)=O)C=CC=C2

InChI

1S/C15H9FO2/c16-10-7-5-9(6-8-10)13-14(17)11-3-1-2-4-12(11)15(13)18/h1-8,13H

InChI key

NASXCEITKQITLD-UHFFFAOYSA-N

Biochem/physiol Actions

Fluindione is an orally active vitamin K antagonist (VKA) that exerts its in vivo anticoagulant efficacy by inhibiting the vitamin K epoxide reductase activity (VKOR IC50 = 6.6 nM) in a substrate-comeptitive manner.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Role of ABC transporters in trans-epithelial transport of vitamin K antagonists
Bernadette Espana , Caroline Prouillac
Biopharmaceutics & Drug Disposition, 38, 20-32 (2017)
Antithrombotic efficacy of the vitamin K antagonist fluindione in a human Ex vivo model of arterial thrombosis : effect of anticoagulation level and combination therapy with aspirin
Bossavy JP, Sakariassen KS, Thalamas C, Boneu B, Cadroy Y
Arteriosclerosis, Thrombosis, and Vascular Biology, 19, 2269-2275 (1999)
Xuejie Chen et al.
Blood, 132(18), 1974-1984 (2018-08-10)
Warfarin, acenocoumarol, phenprocoumon, and fluindione are commonly prescribed oral anticoagulants for the prevention and treatment of thromboembolic disorders. These anticoagulants function by impairing the biosynthesis of active vitamin K-dependent coagulation factors through the inhibition of vitamin K epoxide reductase (VKOR).
Jonaz Font et al.
Fundamental & clinical pharmacology, 32(4), 378-391 (2018-03-12)
Whether oral anticoagulants, vitamin K antagonists (VKAs), and nonvitamin K oral anticoagulant (NOACs) frequently prescribed to atrial fibrillation (AF) patients, do themselves have a pro- or anti-arrhythmic effect have never been addressed. Transmembrane action potentials were recorded in an acute

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service